Comparison Between Combined Suprainguinal Fascia Iliaca Compartment Block with Intraarticular Bupivacaine and Suprainguinal Fascia Iliaca Compartment Block in Total Hip Arthroplasty

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20211006007

Enrollment

Registered

2021-10-06

Start date

2021-10-11

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Combined suprainguinal fascia iliaca compartment block (S-FICB) with intraarticular bupivacaine (IA) in patients undergoing elective primary total hip arthroplasty under spinal anesthesia. Combined suprainguinal fascia iliaca compartment block (S-FICB) with intraarticular bupivacaine (IA) elective primary total hip arthroplasty spinal anesthesia

Interventions

combined suprainguinal fascia iliaca compartment block (S-FICB) with intraarticular bupivacaine (IA) suprainguinal fascia iliaca compartment block (S-FICB) Injection with 40 mL of 0.25%bupivacaine is

Experimental Procedure/Surgery,Experimental Procedure/Surgery

combined suprainguinal fascia iliaca compartment block (S-FICB) with intraarticular bupivacaine (IA) ,suprainguinal fascia iliaca compartment block

Eligibility

Sex/Gender

All

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: patients undergoing total hip arthroplasty

Exclusion criteria

Exclusion criteria: 1.contraindication to local anesthetic or study drugs 2.patients with chronic pain or chronic use of opioids (more than 2 weeks within 1-month) 3.local skin infection at the injection site 4.body mass index > 40 kg/ m2 5.history of renal impairment (CrCl < 30 mg/ml) 6. coagulopathy (platelets < 100,000/mL or INR > 1.4) 7. patients who are unable to assess pain score or unable to operate intravenous patient controlled analgesia (IV-PCA) 8. patients who have contraindications to spinal anesthesia.

Design outcomes

Primary

Measure	Time frame
postoperative 24-hour morphine consumption 24 hr milligram of morphine consumption	—

Secondary

Measure	Time frame
Postoperative pain score at rest and on movement 0,6,12,24,48 Numerical rating scale, NRS 0-11,Time to first morphine requirement within 48 hours questionnaire interview,Incidence of nausea and vomitting within 48 hours questionnaire interview, medical record,Block related complications within 48 hours questionnaire interview, medical record,Patient satisfaction on overall postoperative pain management within 48 hours questionnaire interview,Length of hospital stay Days to weeks Medical record	—

Measure

Time frame

Postoperative pain score at rest and on movement 0,6,12,24,48 Numerical rating scale, NRS 0-11,Time to first morphine requirement within 48 hours questionnaire interview,Incidence of nausea and vomitting within 48 hours questionnaire interview, medical record,Block related complications within 48 hours questionnaire interview, medical record,Patient satisfaction on overall postoperative pain management within 48 hours questionnaire interview,Length of hospital stay Days to weeks Medical record

—

Countries

Thailand

Contacts

Public ContactTheerawat Chalacheewa

Faculty of Medicine Ramathibodi Hospital

drtheerawat@gmail.com022011513

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026